Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 8/20 | 0.32 |
| ▸ | RAMP1 | O60894 | 5/20 | 0.31 |
| ▸ | CALCA | P06881 | 2/20 | 0.30 |
| ▸ | ADM2 | Q7Z4H4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12060708 | 0.86 | CALCRL (0.31) | CALCRLRAMP1CALCA | |
| SCHEMBL12414774 | 0.83 | CA9 (0.32) | CALCRLADM2 | |
| SCHEMBL261335 | 0.68 | CA9 (0.32) | CALCRL | |
| SCHEMBL15935914 | 0.66 | ALDH1A1 (0.42) | CALCRLRAMP1CALCAADM2 | |
| SCHEMBL15227998 | 0.66 | IP6K1 (0.36) | CALCRLRAMP1 | |
| SCHEMBL7033503 | 0.65 | IP6K1 (0.40) | CALCRLRAMP1 | |
| SCHEMBL261045 | 0.65 | TDP2 (0.39) | — | |
| SCHEMBL15935911 | 0.65 | CALCRL (0.39) | CALCRLRAMP1CALCAADM2 | |
| SCHEMBL2522488 | 0.64 | CALCA (0.46) | CALCRLRAMP1CALCAADM2 | |
| SCHEMBL24220794 | 0.63 | CALCA (0.50) | CALCRLRAMP1CALCAADM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133891-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, CALCRL, BDKRB2 | CALCRL 2/4885RAMP1 109/4885CALCA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.